Lycia Therapeutics
CompanyUnited States
Lycia Therapeutics develops 3 assets, the furthest in phase 1 (LCA-0061 in allergic asthma). Mostly other and antibody; based in the United States.
- 3
- Assets
- Furthest stage
- Phase 1
- Raised
- US$377m
- 0
- Trials
- 2
- Signals
Pipeline
3Antibody–small molecule conjugate repeatedly shuttles extracellular IgE into cells for lysosomal degradation.
Phase 1, Other, allergic asthma, allergic rhinitis
Selectively degrades disease-driving thyroid-stimulating hormone receptor autoantibodies through lysosomal targeting.
Phase 1, Graves' disease
Bispecific antibody cataLYTAC degrader designed to degrade multiple IgE molecules per degrader.
Preclinical, Antibody, allergic asthma, allergic rhinitis
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Funding rounds and grants5
- Deals1
- People13
- Signals3
- Similar companies6